References
- Robberecht P, Dekhaye M, Taton G, De Neff P, Waelbroeck M, De Smet J M, Leclerc J L, Chatelain P, Christophe J. The human heart beta-adrenergic receptors. I. Heterogeneity of the binding sites: Presence of 50% beta1- and 50% beta2-adrenergic receptors. Mol Pharmacol 1983; 24: 169–73
- Stiles G L, Taylor S, Lefowitz R J. Human cardiac beta-adrenergic receptors: Subtype heterogeneity delineated by direct radioligand binding. Life Sciences 1983; 33: 467–73
- Brodde O E, Karad K, Zerkowski H-R, Rohm N, Reidemeister J C. Coexistence of β1- and β2-adrenoceptors in human right atrium. Direct identification by (+/-)-[125I]iodocyanopindolol binding. Circ Res 1983; 53: 752–8
- Minneman K P, Molinoff P B. Classification and quantitation of β-adrenergic receptor subtypes. Biochem Pharmacol 1980; 29: 1317–23
- Golf S, Myhre E, Abdelnoor M, Andersen D, Hansson V. Hypertrophic cardiomyopathy (HOCM) characterized by β-adrenoceptor density, relative amount of β-adrenoceptor subtypes and adenylate cyclase activity. Cardiovasc Res 1985; 19: 693–9
- Smith H J, Halliday S E, Earl D CN, Stribling D. Effects of selective (beta-1 and beta-2) and nonselective beta-adrenoceptor antagonists on the cardiovascular and metabolic responses to iso-proterenol: Comparison with ICI 141, 292. J Pharmacol Exp Ther 1983; 226: 211–6
- O'Donnell S R, Wanstall J C. Evidence that ICI 118 551 is a potent highly beta2-selective adrenoceptor antagonist and can be used to characterize beta-adrenoceptor populations in tissues. Life Sciences 1980; 27: 671–7
- Golf S, Jahnsen T, Attramadal H, Frøysaker T, Hansson V. Catecholamine responsive adenylate cyclase activity in human myocardial preparations. Properties and optimalization of assay conditions. Scand J Clin Lab Invest 1984; 44: 317–27
- Golf S, Løvstad R, Hansson V. β-adrenoceptor density and relative number of β-adrenoceptor subtypes in biopsies from human right atrial, left ventricular, and right ventricular myocard. Cardiovasc Res 1985; 19: 636–41
- Minneman K P, Hegstrand L R, Molinoff P B. Simultaneous determination of beta-1 and beta-2 adrenergic receptors in tissues containing both receptor subtypes. Mol Pharmacol 1979; 16: 34–46
- Osmundsen H. A computer programme for the determination of the kinetic constants of two enzymes acting simultaneously on the same substrate. Biochem Biophys Res Commun 1975; 67: 324–30
- Cheng Y-C, Prusoff W H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099–108
- Golf S, Hansson V. Effects of beta-blocking agents on the density of beta adrenoceptors and adenylate cyclase response in human mycardium; intrinsic sympathomimetic activity favours receptor upregulation. Cariovasc Res 1986; 20: 637–44
- Golf S, Hansson V. Relative potencies of various β-adrenoceptor antagonists (BAA) at the level of the human myocardial β-adrenoceptor-adenylate cyclase (AC) complex. Is intrinsic sympathomimetic activity (ISA) due to AC activation?. Scand J Clin Lab Invest 1986; 46: 121–30
- Bilski A, Dorries S, Fitzgerald J D, Jessup R, Tucker H, Wale J. ICI 118 551, a potent β2-adrenoceptor antagonist. Br J Pharmacol 1980; 69: 292P–293P
- Bristow M R, Ginsburg R. Beta2 receptors on myocardial cells in human ventricular myocardium. Am J Cardiol 1986; 57: 3F–6F